Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019063841) CUTANEOUS PAPILLOMA VIRUS VACCINE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/063841 International Application No.: PCT/EP2018/076651
Publication Date: 04.04.2019 International Filing Date: 01.10.2018
IPC:
A61K 39/12 (2006.01) ,C07K 16/08 (2006.01) ,C07K 14/005 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08
against material from viruses
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005
from viruses
01
DNA viruses
03
Herpetoviridae, e.g. pseudorabies virus
05
Epstein-Barr virus
Applicants:
DEUTSCHES KREBSFORSCHUNGSZENTRUM [DE/DE]; Im Neuenheimer Feld 280 69120 Heidelberg, DE
Inventors:
MÜLLER, Martin; DE
OTTONELLO, Simone; IT
BOLCHI, Angelo; IT
MARIZ, Filipe; DE
ZHAO, Xueer; DE
BALZ, Kathrin; DE
Agent:
DICK, Alexander; HERZOG FIESSER & PARTNER PATENTANWÄLTE PARTG MBB Dudenstraße 46 68167 Mannheim, DE
Priority Data:
17194145.329.09.2017EP
Title (EN) CUTANEOUS PAPILLOMA VIRUS VACCINE
(FR) VACCIN CONTRE LE PAPILLOMAVIRUS CUTANÉ
Abstract:
(EN) The present invention relates to an immunogenic polypeptide comprising a multitude of papillomavirus (PV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least four different cutaneous HPV genotypes; and to the aforesaid immunogenic polypeptide for use in medicine and for use in vaccination of a subject against cutaneous HPV infection and/or mucosal HPV infection. The present invention further relates to a polynucleotide encoding the aforesaid immunogenic polypeptide and to vectors, host cells, methods for producing an antibody, as well as antibodies relatedthereto.
(FR) La présente invention concerne un polypeptide immunogène comprenant une multitude de peptides N-terminaux de L2 de papillomavirus (PV) correspondant aux acides aminés 20 à 50 du polypeptide L2 de PVH16, lesdits peptides N-terminaux de L2 de PVH étant des peptides N-terminaux de L2 provenant d'au moins quatre génotypes de PVH cutanés différents ; et le polypeptide immunogène mentionné ci-dessus destiné à être utilisé en médecine et destiné à être utilisé dans la vaccination d'un sujet contre une infection par un PVH cutané et/ou une infection par un PVH muqueux. La présente invention concerne en outre un polynucléotide codant le polypeptide immunogène susmentionné et des vecteurs, des cellules hôtes, des procédés de production d'un anticorps, ainsi que des anticorps associés à ceux-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)